Mountain Pacific Investment Advisers Inc. ID Sells 178 Shares of Johnson & Johnson (NYSE:JNJ)

Mountain Pacific Investment Advisers Inc. ID lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.8% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 21,386 shares of the company’s stock after selling 178 shares during the quarter. Mountain Pacific Investment Advisers Inc. ID’s holdings in Johnson & Johnson were worth $3,383,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Keener Financial Planning LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter worth $40,000. WFA Asset Management Corp grew its stake in shares of Johnson & Johnson by 61.4% in the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock worth $40,000 after purchasing an additional 97 shares during the last quarter. Vermillion & White Wealth Management Group LLC acquired a new position in Johnson & Johnson in the fourth quarter valued at $44,000. Disciplined Equity Management Inc. acquired a new position in Johnson & Johnson in the fourth quarter valued at $45,000. Finally, Grayhawk Investment Strategies Inc. lifted its holdings in Johnson & Johnson by 528.6% in the fourth quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock valued at $48,000 after buying an additional 259 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.7 %

Shares of NYSE:JNJ traded up $0.97 on Friday, hitting $148.75. The company had a trading volume of 15,176,869 shares, compared to its average volume of 6,685,153. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $175.97. The firm has a market capitalization of $357.99 billion, a price-to-earnings ratio of 9.27, a P/E/G ratio of 2.46 and a beta of 0.53. The firm’s 50-day simple moving average is $148.05 and its two-hundred day simple moving average is $154.35. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The business had revenue of $21.38 billion during the quarter, compared to analysts’ expectations of $21.39 billion. During the same period in the previous year, the company earned $2.68 earnings per share. The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. Equities analysts anticipate that Johnson & Johnson will post 10.63 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were paid a $1.24 dividend. The ex-dividend date of this dividend was Monday, May 20th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.33%. Johnson & Johnson’s payout ratio is currently 30.92%.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on JNJ shares. Royal Bank of Canada reiterated an “outperform” rating and set a $175.00 price objective on shares of Johnson & Johnson in a report on Monday, June 17th. StockNews.com lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Saturday. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Thursday. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their target price for the stock from $169.00 to $170.00 in a research report on Thursday, April 18th. Finally, Bank of America decreased their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Eight equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Hold” and an average price target of $174.07.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.